HCW Biologics Inc. (HCWB)
| Market Cap | 62.79M |
| Revenue (ttm) | 560,360 |
| Net Income (ttm) | -24.99M |
| Shares Out | 37.82M |
| EPS (ttm) | -0.70 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,566 |
| Open | 1.500 |
| Previous Close | 1.590 |
| Day's Range | 1.500 - 1.670 |
| 52-Week Range | 0.910 - 2.320 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+442.17%) |
| Earnings Date | May 7, 2024 |
About HCWB
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as... [Read more]
Financial Performance
In 2023, HCW Biologics's revenue was $560,360, a decrease of -78.33% compared to the previous year's $2.59 million. Losses were -$24.99 million, 67.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for HCWB stock is "Strong Buy" and the 12-month stock price forecast is $9.0.
News
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing...
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...
Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Showed HCW9218 clinical safety and tumor response endpoints for 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable ...
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months Company will provide an update f...
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent Cells in Subjects with Cancer Allowed Methods of Use Claims Direc...
HCW Biologics Reports First Quarter 2023 Financial Results And Recent Business Highlights
MIRAMAR, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing n...
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Compan...
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE NEWSWIRE...
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
HCW Biologics Published a Pivotal Scientific Paper in Aging Cell
HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
MIRAMAR, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing...
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advan...
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform
Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting
Presentation includes data on safety and dosage escalation and immune system reaction to HCW9218
HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights
MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...
HCW Biologics Inc (HCWB), Quotient Technology (QUOT) – Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
US crude oil futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.
CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying
The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades.
HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights
MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...
U.S. Patent Issued to HCW Biologics for Foundational Platform Technology
Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Product Candidate, HCW9302 Issued Claims for Single-Chain Chimeric Polypeptide and Composition Claims for Lead Produ...
HCW Biologics to Participate in H.C. Wainwright Annual Global Life Sciences Conference May 23 – 25, 2022
MIRAMAR, Fla., May 23, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapie...
HCW Biologics Reports First Quarter 2022 Financial Results and Recent Business Highlights
MIRAMAR, Fla., May 13, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunother...
HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists
Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells Without Using Feeder Cells Sufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy
HCW Biologics' CEO Hing C. Wong, Ph.D.
Preclinical data for lead investigational drug, HCW9218, in treatment of therapy-induced senescence in cancer
HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights for 2021
$56 Million IPO Completed in July 2021 Expected to Fund Operating Expenses through 2023